TTPH Tetraphase Pharmaceuticals Inc.

6.55
-0.29  -4%
Previous Close 6.84
Open 6.80
Price To book 3.12
Market Cap 334400084
Shares 51,053,448
Volume 1,060,714
Short Ratio 3.41
Av. Daily Volume 1,479,895

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial did not meet endpoints September 2015. Additional Phase 3 trial initiation announced January 17, 2016. Completion of enrollment announced September 11, 2017. Data due 1Q 2018.
Eravacycline (TP-434) - IGNITE3
cUTI - complicated urinary tract infections
Phase 3 data released July 25, 2017 - primary endpoint met. NDA filing due 1Q 2018.
Eravacycline (TP-434) - IGNITE4
cIAI (complicated intra-abdominal infections)

Latest News

  1. Tetraphase Pharmaceuticals Completes Enrollment of IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections
  2. Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
  3. ETFs with exposure to Tetraphase Pharmaceuticals, Inc. : September 1, 2017
  4. Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : TTPH-US : August 31, 2017
  5. Tetraphase Pharmaceuticals, Inc. :TTPH-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  6. Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency
  7. Options Traders Expect Huge Moves in Tetraphase Pharmaceuticals (TTPH) Stock
  8. 3 Game-Changing Small-Cap Healthcare Stocks
  9. Tetraphase Pharmaceuticals, Inc. – Value Analysis (NASDAQ:TTPH) : August 4, 2017
  10. Tetraphase reports 2Q loss
  11. Tetraphase Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Achievements
  12. Tetraphase Pharma Decides to Reap Profits With Secondary Offering
  13. Tetraphase Announces Pricing of Public Offering of Common Stock
  14. Why Tetraphase Pharmaceuticals Fell 11.7% Today
  15. Today's Research Reports on Stocks to Watch: Argos Therapeutics and Tetraphase Pharmaceuticals
  16. Tetraphase Announces Proposed Public Offering of Common Stock
  17. Tetraphase Pharmaceuticals Inc (TTPH) Investors Are Parading Today, But Needham Cautious on the Long-Term
  18. Here's Why Tetraphase Pharmaceuticals Rose as Much as 26.8% Today
  19. Watertown’s Tetraphase says antibiotic clears late-stage hurdle

SEC Filings

  1. CT ORDER - Confidential treatment order 171096634
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171020507
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17999928
  4. 8-K - Current report 17990046
  5. 424B5 - Prospectus [Rule 424(b)(5)] 17989992
  6. 424B5 - Prospectus [Rule 424(b)(5)] 17984297
  7. 8-K - Current report 17980677
  8. 8-K - Current report 17955641
  9. 424B5 - Prospectus [Rule 424(b)(5)] 17955614
  10. EFFECT - Notice of Effectiveness 17950771